Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0990 • ACR Convergence 2023
Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry
Kelly Gavigan¹, Esteban Rivera², Odette Kolenky³, Cassie Clinton⁴, Emily Holladay⁴, David Curtis⁵, Laura Stradford⁶, Jeffrey Curtis⁴, W. Benjamin Nowell⁶, Christian Curtis⁷ and Michael George⁸, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, Long Island City, NY, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, San Francisco, CA, ⁶Global Healthy Living Foundation, Nyack, NY, ⁷Illumination Health, Birmingham, AL, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Infections are a major contributor to morbidity and mortality in patients (pts) with rheumatoid arthritis (RA). Little is known about the risk of non-serious…
Abstract Number: 1064 • ACR Convergence 2023
Seroconversion Rates in Rituximab-Treated Rheumatic Patients Receiving COVID-19 Vaccination
Ryan Wilson¹, Junaid Awan², Mary Brady², Ciara Hunt², Fahd Adeeb³ and alexander fraser⁴, ¹University of Limerick, Buncrana, Ireland, ²University of Limerick, Limerick, Ireland, ³RCSI & UCD (Ireland) Malaysia Campus (RUMC), Malaysia, Malaysia, ⁴HSE, Limerick, Ireland
Background/Purpose: COVID-19 has increased the mortality rates among rheumatic patients, mainly those immunocompromised or with underlying comorbidities. During the COVID-19 vaccine development, patients on immunomodulatory…
Abstract Number: 1270 • ACR Convergence 2023
Identification of Subclinical Atherosclerosis by Six Cardiovascular Risk Calculators in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui¹, José Ramón Azpiri-López², Dionicio A. Galarza-Delgado², Iris Colunga², Jesus Alberto Cardenas-De la Garza³ and Rosa Arvizu-Rivera⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico
Background/Purpose: Current EULAR recommendations for cardiovascular risk (CVR) assessment in rheumatoid arthritis (RA) patients indicate that the CVR evaluation should be performed according to national…
Abstract Number: 1286 • ACR Convergence 2023
Impact of Body Mass Index (BMI) on Upper versus Lower Extremity Joints Assessed Using Clinical and Musculoskeletal Ultrasound Measures in Rheumatoid Arthritis Patients
Nicolette Morris¹, Elena Saab², Lucia Chen¹, Jenny Brook¹, Gurjit S Kaeley³, David Elashoff¹ and Veena Ranganath¹, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Wake Forest University School of Medicine, Los Angeles, CA, ³University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL
Background/Purpose: Tender and swollen joints counts may be differentially affected in rheumatoid arthritis (RA) patients with obesity. A prior study demonstrated an association between increased…
Abstract Number: 1302 • ACR Convergence 2023
Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study
Daniel Solomon¹, Olga Demler², Pamela Rist², Leah Santacroce¹, Jon Giles³, Katherine Liao¹ and Joan Bathon³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Columbia University, New York, NY
Background/Purpose: Cardiovascular (CV) disease remains an important source of morbidity and the most common cause of mortality in patients with rheumatoid arthritis (RA). It has…
Abstract Number: 1318 • ACR Convergence 2023
Abatacept Modulates Both Global and Citrulline Specific T Cell Signatures: Results from Inhibition of Co-Simulation in Rheumatoid Arthritis Phase IV Trial
Ravi Kumar Sharma¹, Aysin Tulunay Virlan², Louise Bennett³, John Cole³, Sam McAllister², Sara Turcinov⁴, Samantha Miller³, Fraser Morton³, Ashley Gilmour³, Sean Kerrigan³, Anatoly Dubnovitsky¹, Leonid Padyukov⁵, Caron Paterson³, William Kwok⁶, René Toes⁷, Lars Klareskog⁸, Arthur Pratt⁹, John Isaacs¹⁰, Sean Connolly¹¹, Duncan Porter³, Stefan Siebert¹², Iain McInnes³, Vivianne Malmström⁸ and Carl Goodyear³, ¹Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ³University of Glasgow, Glasgow, United Kingdom, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Solna, Sweden, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Immunity and Inflammation Theme, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom, ¹⁰Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Unit, Newcastle Hospitals, Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²School of Infection and Immunity, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Clinical outcomes in Rheumatoid arthritis (RA) have improved with the introduction of biological and targeted synthetic disease modifying anti-rheumatic drugs (b & tsDMARDs). Abatacept…
Abstract Number: 1335 • ACR Convergence 2023
Effectiveness of Longstanding Exercise Therapy versus Usual Care in People with Rheumatoid Arthritis and Severe Functional Limitations: A Randomized Controlled Trial (L-EXTRA)
Max Teuwen¹, Salima van Weely¹, Thea Vliet Vlieland², Manja van Wissen¹, Wilfred Peter¹, Alfons den Broeder³, Dirkjan van Schaardenburg⁴, Wilbert van den Hout¹, Cornelia van den Ende³ and Maaike gademan¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leids University Medical Center, Leiden, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Reade, Amsterdam, Netherlands
Background/Purpose: Supervised exercise therapy is an effective and safe treatment option for people with rheumatoid arthritis (RA). However, most studies involve interventions of relatively short…
Abstract Number: 1526 • ACR Convergence 2023
Evusheld Efficacy and Safety in Autoimmune Rheumatic Diseases (AIRD) Treated by B Cell Depeting Therapy or Autologous Stem Cell Transplantation: A Prospective Observational Study
Lisa Kaly¹, mark Volevich¹, shiri keret², Abid Awisat³, Aniela Shouval¹, Itzhak Rosner⁴, Michel Rozenbaum¹, Nina Boulman¹ and Doron Rimar¹, ¹Bnai Zion Medical Center, Haifa, Israel, ²Bnai Zion, Atlit, Israel, ³Bney-Zion Medical Center, Baqa Elgharbiya, Israel, ⁴Bnai Zion Medical Center/Technion, Haifa, Israel
Background/Purpose: B cell depleting therapy (rituximab) and Autologous Hematopoietic Stem Cell transplantation (AHSCT) result in impaired ability to mount a humoral immune response. Evusheld (tixagevimab…
Abstract Number: 1713 • ACR Convergence 2023
Prevention of Arthritis Development by Mechanical Unloading Through Inhibition of CCL2 and YAP-mediated Inflammation in the Rat Adjuvant-induced Arthritis Model
Elisa Dalix¹, Mathieu Maalouf¹, Robin Caire², Guillaume Courbon¹, Virginie Dumas³, Sylvie Peyroche¹, Marie-Thérèse Linossier¹, Mireille Thomas¹, Charles-Antoine Arthaud¹, Arnaud Vanden-Bossche¹ and Hubert Marotte⁴, ¹Université Jean Monnet Saint-Étienne, Mines Saint-Etienne, INSERM, Saint-Etienne, France, ²Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy, ³Laboratory of Tribology and Systems Dynamics, Ecole Nationale d'Ingénieurs de Saint Etienne, Ecole Centrale de Lyon, University of Lyon, Saint-Etienne, France, ⁴CHU Saint-Etienne, Saint-Etienne, France
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease, characterized by synovitis associated with progressive bone loss and joint degradation. The adjuvant-induced…
Abstract Number: 1736 • ACR Convergence 2023
The Effect of Resolvin E1 and Resolvin D1 Specialised Pro-resolving Mediators on the Inhibition of Osteoclastogenesis
Patricia Riedlova¹, Kieran Woolcock², Cecilia Ansalone² and Carl Goodyear², ¹University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Osteoclasts (OCs) are multinucleated bone-resorbing cells playing a key role in rheumatoid arthritis (RA). Under physiological conditions, OCs are in balance with bone-forming osteoblasts,…
Abstract Number: 1752 • ACR Convergence 2023
Fibroblast Expression of Neurotransmitter Receptor HTR2A Associates with Inflammation in Rheumatoid Arthritis Joint
Chunyan Xiang¹, Soomin Hong¹, Bingjiao Zhao², Hui Pi³, Fang Du⁴, Xingyu Lu⁵, Yuanjia Tang¹, Nan Shen⁶, Chunxi Yang⁷ and Runci Wang⁸, ¹Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ²Department of Orthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China, ³Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China, ⁴Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ⁵Department of Endocrinology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁶Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁷Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ⁸Renji hospital, Shanghai Jiaotong University, Pudong Xinqu, China
Background/Purpose: Peripheral neuroimmune crosstalk plays a crucial role in the inflammatory process and bone metabolism in joint. Serotonin receptor HTR2A was reported to be expressed…
Abstract Number: 1768 • ACR Convergence 2023
The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study
Christopher Rooney¹, Ian Jeffery², Kulveer Mankia³, Mark Wilcox¹ and Paul Emery⁴, ¹University of Leeds, Leeds, United Kingdom, ²4D Pharma plc, Cork, Ireland, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Multiple compositional shifts of gut microbiota have been identified within the rheumatoid arthritis (RA) disease continuum, encompassing both established RA and at-risk individuals (including…
Abstract Number: 1867 • ACR Convergence 2023
Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography
Mathias Hänel¹, Rasmus Klose-Jensen², Josephine Therkildsen³, Anne-Birgitte Garm Blavnsfeldt³, Bente Langdahl³, Stinus Gadegaard Hansen⁴, Kresten Keller⁵ and Ellen Margrethe Hauge³, ¹Rheumatollogy, Aarhus University Hospital, Aarhus, Denmark, ²Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Odense University Hospital, Svendborg Sygehus, Svendborg, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: High resolution peripheral quantitative computed tomography (HR-pQCT) is a promising imaging modality for assessing volumetric bone mineral density (BMD) in rheumatoid arthritis (RA), and…
Abstract Number: 2021 • ACR Convergence 2023
Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy
Juan Ruiz¹, Sheneze Madramootoo², Maria A. Lopez-Olivo¹, Namrata Singh³ and Maria Suarez-Almazor⁴, ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³University of Washington, Bellevue, WA, ⁴MD Anderson Cancer Center, Houston, TX
Background/Purpose: Treatment of rheumatoid arthritis (RA) in patients with cancer could potentially result in poor cancer outcomes because of immunosuppression. Adequate data for shared decision-making…
Abstract Number: 2106 • ACR Convergence 2023
Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls
Stephen Oakley¹, Samantha Stott¹, Kerri Gill¹, Chan Virgil¹, Lyanne Weston² and Theo de Malmanche¹, ¹John Hunter Hospital, New Lambton, Australia, ²Australian Red Cross Blood Service, Alexandria, Australia
Background/Purpose: The risk of developing ACPA+RA, predictors of severity and causes of excess cardiovascular disease (CVD) are incompletely understood. We have observed that RA patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].